Mason, I’ll turn it over to you on Folex which has probably been the biggest single impact we’ve had as a company. At a high level, we’ve been especially impacted internationally in the ...

The company's third-quarter adjusted EBITDA and sales fell short of the previous year's figures. American Vanguard is facing pressures from generic competitors, particularly on its Folex product.

Well, again, I'll start at a high level. Mason, I'll turn it over to you on Folex which has probably been the biggest single impact we've had as a company. At a high level, we've been especially ...